Homocysteine in vascular behçet disease: A meta-analysis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 10, 2010, Pages 2067-2074

  La Regina, Micaela ^a   Orlandini, Francesco ^a   Prisco, Domenico ^b   Dentali, Francesco ^c  

^a Ligurian East Hospital   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Beh et disease; homocysteine; metaanalysis; thrombosis; vascular manifestations

Indexed keywords

HOMOCYSTEINE;

ARTERY THROMBOSIS; ARTICLE; BEHCET DISEASE; DISEASE ASSOCIATION; HUMAN; HYPERHOMOCYSTEINEMIA; PRIORITY JOURNAL; RISK FACTOR; UVEITIS; VASCULAR DISEASE; VASCULITIS; VEIN THROMBOSIS; ADULT; BLOOD; META ANALYSIS; THROMBOSIS;

ADULT; BEHCET SYNDROME; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; RISK FACTORS; THROMBOSIS;

EID: 77957704040     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.207068     Document Type: Article

References (47)

1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med. 1999;341:1284-1291.
2. Koç Y, Güllü I, Akpek G, Akpolat T, Kansu E, Kiraz S, Batman F, Kansu T, Balkanci F, Akkaya S. Vascular involvement in BD. J Rheumatol. 1992;19(3):402-410.
3. Grays GS. The triple complex syndrome of Behçet. Can Med Assoc J. 1950;62:597-599.
4. Lee YJ, Kang SW, Yang JI, Choi YM, Sheen D, Lee EB, Choi SW, Song YW. Coagulation parameters and plasma total homocysteine levels in Behçet's disease. Thromb Res. 2002;106:19-24.
5. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, Inbal A, Many A, Lubetsky A, Varon D, Martinowitz U, Seligsohn U. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol. 1999;19:511-518.
6. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost. 2001;86:809-816.
7. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J. 2003;146:948-957.
8. Leiba M, Seligsohn U, Sidi Y, Harats D, Sela BA, Griffin JH, Livneh A, Rosenberg N, Gelernter I, Gur H, Ehrenfeld M. Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease. Ann Rheum Dis. 2004;63:1445-1449.
9. Navarro S, Ricart JM, Medina P, Vaya A, Villa P, Todolí J, Estelles A, Mico ML, Aznar J, España F. Activated protein C levels in Behcet's disease and risk of venous thrombosis. Br J Haematol. 2004;126: 550-556.
10. Koçsar A, Ozturk M, Haznedaroglu IC, Karaaslan Y. Hemostatic parameters in Behcet's disease: a reappraisal. Rheumatol Int. 2002;22:9-15.
11. Kiraz S, Ertenli I, Ozturk MA, Haznedaroglu IC, Çelik I, Çalguneri M. Pathological haemostasis and "prothrombotic state" in Behcet's disease. Thromb Res. 2002;105:125-133.
12. Ricart JM, Vaya A, Todolí J, Calvo J, Villa P, Estelles A, España F, Santaolaria M, Corella D, Aznar J. Thrombophilic risk factors and homocysteine levels in Behcet's disease in eastern Spain and their association with thrombotic events. Thromb Haemost. 2006;95:618-624.
13. Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C-T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med. 2007;167:497-501.
14. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996;334:759-762. (Pubitemid 26089357)
15. Van Guelpen B, Hultdin J, Johansson I, Witthoft C, Weinehall L, Eliasson M, Hallmans G, Palmqvist R, Jansson JH, Winkvist A. Plasma folate and total homocysteine levels are associated with the risk of myocardial infarction, independently of each other and of renal function. J Intern Med. 2009;266:182-195.
16. Sofi F, Lari B, Rogolino A, Marcucci R, Pratesi G, Dorigo W, Pratesi C, Gensini GF, Abbate R, Prisco D. Thrombophilic risk factors for symptomatic peripheral arterial disease. J Vasc Surg. 2005;41:255-260.
17. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Renne D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc. 2000;283:2008-2012
18. International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990;335:1078-1080.
19. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, Guyatt G, for Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine, 3: measures of observer variability (kappa statistic). CMAJ. 2004;171:1369-1373.
20. Maclure M, Willett WC. Misinterpretation and misuse of the kappa statistic. Am J Epidemiol. 1987;126:161-169.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327:557-560.
22. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
23. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. Br Med J. 2001;323:101-105.
24. Yesilova Z, Pay S, Oktenli C, Musabak U, Saglam K, Sanisoglu SY, Dagalp K, Erbil MK, Kocar IH. Hyperhomocysteinemia in patients with Behcet's disease: is it due to inflammation or therapy? Rheumatol Int. 2005;25:423-428.
25. Ates A, Aydintug O, Olmez Ü, Düzgün N, Duman M. Serum homocysteine level is higher in Behcet's disease with vascular involvement. Rheumatol Int. 2005;25:42-44.
26. Altinbaçs A, Aytemur K, Tokgozoglu L, Ozturk M, Koçsar A, Haznedaroglu IC, Kirazli S, Dündar SV. Hyperhomocysteinemia and activated protein C resistance in Behcet's disease. J Intern Med. 2000;248: 267-268.
27. Canataroglu A, Tanriverdi K, Inal T, Seydaoglu G, Arslan D, Ozbek S, Baslamisli F. Methylenetetrahydrofolate reductase gene C677T mutation and plasma hcy level in Behcet's disease. Rheumatol Int. 2003;23: 236-240.
28. Kayikcioglu M, Aksu K, Hasdemir C, Keser G, Turgan N, Kultursay H, Doganavsargil E. Endothelial functions in Behcet's disease. Rheumathol Int. 2006;26:304-308.
29. Nazarinia MA, Aflaki E, Habibaghahl Z, Rajaee A, Omrani GR. Serum homocysteine level and vascular thrombosis in patients with Behçet's disease. J Rheumatol. 2007;10:178-181.
30. Korkmaz C, Bozan B, Kosar M, Sahin F, Gülbas Z. Is there an association of plasma hcy levels with vascular involvement in patients with Behçet's syndrome? Clin Exp Rheumatol. 2002;20:S30-S34.
31. Sentürk Ö, Ö zgur O, Hülagü S, Cantürk NZ, Ç elebi A, Karakaya T. Effect of Helicobacter pylori infection on deep vein thrombosis seen in patients with Behçet's disease. East African Med J. 2006;83:49-51.
32. Düzgün N, Duman T, Morris Y, Tutkak H, Ksöe K, Ertug?rul E, Tiryaki Aydmtug? O. Thymidylate synthase genotype and serum concentrations of homocysteine and folate in Behçet's disease. Clin Rheumatol. 2008;27: 1221-1225.
33. Durmazlar SPK, Akgul A, Eskioglu F. Homocysteine may involve in the pathogenesis of Behçet's disease by inducing inflammation. Mediat Inflamm. 2008;1-9.
34. Feki M, Houman H, Gannouchi M, Smiti-Khanfir M, Hamazoui K, El Matri L, Mebazaa A, Kaabachi N. Hyperhomocysteinemia is associated with uveitis but not with deep venous thrombosis in Behçet's disease. Clin Chem Lab Med. 2004;42:1417-1423.
35. Houman H, Feki M, Ghorbel B, Gadhoum H, Hsairi M, Omar S, Lamloum M, Kaabachi N, Mebazaa A, Miled M. Does hyperhomocys-teinemia increase the risk of thrombosis in Behçet's disease? In: Zouboulis C, ed. Adamantiades- Behçet's Disease. New York: Kluwer Academic/Plenum Publishers; 2003;413-417.
36. Aksu K, Turgan N, Oksel F, Keser G, Ö zmen D, Kitapçiog?lu G, Gümüçsdiçs G, Bayindir O, Dog?anavçsargil E. Hyperhomocysteinemia in Behçet's disease. Rheumatology. 2001;40:687-690.
37. Zappacosta B, Persichillki S, Scribano D, Minucci A, Lazzaro D, De Sole P, Giardina B. Comparing different methods for homocysteine determination. Clin Chem Lab Med. 2002;40(11):1139-1142.
38. Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. J Nutr. 1996;126:1285S-1289S.
39. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050. (Pubitemid 128753793)
40. Midorikawa S, Sanada H, Hashimoto S, Watanabe T. Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells. Biochem Biophys Res Commun. 2000;272:182-185.
41. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulphate expression in cultured porcine aortic endothelial cells. J Clin Invest. 1993;92:1381-1386.
42. Monnerat C, Hayoz D. Homocysteine and venous thromboembolism. Schweiz Med Wochenschr. 1997;127:1489-1496.
43. den Heijer M, Brouwer IA, Bos GM, Blom HJ, van der Put NM, Spaans AP, Rosendaal FR, Thomas CM, Haak HL, Wijermans PW, Gerrits WB. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol. 1998;18:356-361.
44. Houman MH, Naffati H, Khanfir M, Ghannouchi M, Ben Ghorbel I, Lamloum M, El Matri L, Hamzaoui K, Jeddi A, Miled M, Fki M. Does lowering hyperhomocysteinemia by folic acid beneficial for oculo-Behçet's disease? A pilot study. Tunis Med. 2007;85:450-453.
45. den Heijer M, Willems HP, Blom HJ, Gerrits WB, Cattaneo M, Eichinger S, Rosendaal FR, Bos GM. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood. 2007;109: 139-144.
46. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. J Am Med Assoc. 2004;291:565-575.
47. Bonaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K, NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-1588.